{"altmetric_id":24020726,"counts":{"readers":{"mendeley":2,"citeulike":0,"connotea":0},"total":{"posts_count":22},"twitter":{"unique_users_count":18,"unique_users":["pancreophil","GIcancerDoc","heatherahannon","mdmanishshah","JournalCancer","Camicol1","leenakorpinen","AV_icu","talbotrlibrary","jdarsee","giconnectInfo","jlepping2013","DrAmitDangi","bmassutis","AngelesYrbas","lopezgovlaw","MiamiGives","ccsainc"],"posts_count":21},"facebook":{"unique_users_count":1,"unique_users":["554459631334994"],"posts_count":1}},"selected_quotes":["Patients w\/ #PancreaticCancer who received 2nd line fluoropyrimidine combo tx showed improved survival vs. FP alone","2nd line tx in patients w\/ pancreatic ductal adenocarcinoma: A meta-analysis","Pts w\/ #PanCan treated w\/ OX or various IRI formulations appeared to have improved progression-free survival","#pancreaticcancer Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Be\u2026"],"citation":{"abstract":"There are limited therapeutic options for treatment-refractory pancreatic ductal adenocarcinoma (PDAC), with a paucity of data to support the best option after progression on gemcitabine-based regimens. The authors performed a meta-analysis to determine the effectiveness of adding oxaliplatin (OX) or various irinotecan formulations to a fluoropyrimidine (FP) after first-line treatment progression in patients with PDAC.\nDifferent databases, including PubMed, EMBASE, and Cochrane, were searched to identify randomized controlled trials comparing FP monotherapy versus FP combination therapy that included either oxaliplatin (FPOX) or various irinotecan formulations (FPIRI) in patients with PDAC who progressed after first-line treatment. Secondary analyses were planned to assess the effectiveness of FPOX and FPIRI compared with FP. Outcomes of interest included overall survival (OS) and progression-free survival (PFS).\nFive studies with 895 patients were identified. Patients randomized to receive FPIRI\/FPOX had a significantly improved PFS and a trend toward improved OS compared with those who received FP monotherapy. When comparing FPIRI with FP, there was an improvement in both PFS (hazard ratio, 0.64; 95% confidence interval, 0.47-0.87; P = .005) and OS (hazard ratio, 0.70; 95% confidence interval, 0.55-0.89; P = .004) in patients who received the combination. Conversely, FPOX produced only a modest improvement in PFS with no improvement in OS.\nCombination chemotherapy with OX or various IRI formulations appears to improve PFS compared with single-agent FP. FPIRI, but not FPOX, appears to confer an OS advantage. The combination of FP with irinotecan formulations appears to be the appropriate next line of treatment upon progression after gemcitabine-based chemotherapy regimens. Cancer 2017. \u00a9 2017 American Cancer Society.","altmetric_jid":"4f6fa4e93cf058f610002494","authors":["Sonbol, Mohamad Bassam","Firwana, Belal","Wang, Zhen","Almader-Douglas, Diana","Borad, Mitesh J.","Makhoul, Issam","Ramanathan, Ramesh K.","Ahn, Daniel H.","Bekaii-Saab, Tanios","Almader\u2010Douglas, Diana","Bekaii\u2010Saab, Tanios"],"doi":"10.1002\/cncr.30927","first_seen_on":"2017-08-18T10:06:32+00:00","funders":["niehs"],"handles":[],"issns":["0008-543X","1097-0142"],"journal":"Cancer (0008543X)","last_mentioned_on":1504654098,"links":["https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28817187?dopt=Abstract","http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30927\/full\/","http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30927\/full"],"pdf_url":"http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30927\/pdf","pmid":"28817187","pubdate":"2017-08-17T00:00:00+00:00","publisher":"Wiley-Blackwell","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/secondline-treatment-patients-pancreatic-ductal-adenocarcinoma-metaanalysis"},"altmetric_score":{"score":9.65,"score_history":{"1y":9.65,"6m":9.65,"3m":9.65,"1m":9.65,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":9.65},"context_for_score":{"all":{"total_number_of_other_articles":8366342,"mean":7.0541652571821,"rank":912644,"this_scored_higher_than_pct":89,"this_scored_higher_than":7452375,"rank_type":"exact","sample_size":8366342,"percentile":89},"similar_age_3m":{"total_number_of_other_articles":153865,"mean":12.802562210784,"rank":24525,"this_scored_higher_than_pct":84,"this_scored_higher_than":129277,"rank_type":"exact","sample_size":153865,"percentile":84},"this_journal":{"total_number_of_other_articles":5840,"mean":13.65328926186,"rank":1090,"this_scored_higher_than_pct":81,"this_scored_higher_than":4749,"rank_type":"exact","sample_size":5840,"percentile":81},"similar_age_this_journal_3m":{"total_number_of_other_articles":84,"mean":38.77934939759,"rank":39,"this_scored_higher_than_pct":53,"this_scored_higher_than":45,"rank_type":"exact","sample_size":84,"percentile":53}}},"demographics":{"poster_types":{"member_of_the_public":11,"researcher":3,"practitioner":3,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":11,"Scientists":3,"Practitioners (doctors, other healthcare professionals)":3,"Science communicators (journalists, bloggers, editors)":1}},"mendeley":{"by_status":{"Professor > Associate Professor":1,"Student  > Ph. D. Student":1},"by_discipline":{"Medicine and Dentistry":1,"Biochemistry, Genetics and Molecular Biology":1}}},"geo":{"twitter":{"US":8,"FI":1,"IN":1,"AR":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/pancreophil\/statuses\/898486180454453250","license":"gnip","citation_ids":[24020726],"posted_on":"2017-08-18T10:06:13+00:00","author":{"name":"pancreophil","image":"https:\/\/pbs.twimg.com\/profile_images\/699064292465864706\/XVzBpUC6_normal.jpg","id_on_source":"pancreophil","tweeter_id":"4911466401","geo":{"lt":null,"ln":null},"followers":211},"tweet_id":"898486180454453250"},{"url":"http:\/\/twitter.com\/GIcancerDoc\/statuses\/899032613519851521","license":"gnip","citation_ids":[24020726],"posted_on":"2017-08-19T22:17:32+00:00","author":{"name":"Tanios Bekaii-Saab","image":"https:\/\/pbs.twimg.com\/profile_images\/739561302809583616\/hVYUvCQo_normal.jpg","description":"#Pancreas #Colorectal #Biliary #Liver #Gastric #Esophagus #SmallBowel #Genomics #TargetedTherapies #Immunotherapy","id_on_source":"GIcancerDoc","tweeter_id":"4756413976","geo":{"lt":33.50921,"ln":-111.89903,"country":"US"},"followers":373},"tweet_id":"899032613519851521"},{"url":"http:\/\/twitter.com\/heatherahannon\/statuses\/899033523146768384","license":"gnip","rt":["GIcancerDoc"],"citation_ids":[24020726],"posted_on":"2017-08-19T22:21:09+00:00","author":{"name":"Heather Hannon","image":"https:\/\/pbs.twimg.com\/profile_images\/883126721637216256\/UC9jYotX_normal.jpg","description":"Oncology Nurse Practitioner, Science nerd, Autism advocate, Foo Fighters fan, 5SOS enthusiast, Marvel girl, Coffee addict, Mom to 4 great kids. Opinions my own","id_on_source":"heatherahannon","tweeter_id":"336908716","geo":{"lt":37.54812,"ln":-77.44675,"country":"US"},"followers":254},"tweet_id":"899033523146768384"},{"url":"http:\/\/twitter.com\/mdmanishshah\/statuses\/899331367820959744","license":"gnip","rt":["GIcancerDoc"],"citation_ids":[24020726],"posted_on":"2017-08-20T18:04:41+00:00","author":{"name":"Manish A. Shah","url":"http:\/\/weillcornell.org\/physician\/mashah\/index.html","image":"https:\/\/pbs.twimg.com\/profile_images\/882448832642134016\/uZHaxMmY_normal.jpg","description":"Father, husband, oncologist @MeyerCancer, researcher. Things we do matter! Chief Solid Tumor Service @WeillCornell @NYPhospital Chair @ASCO CPGC","id_on_source":"mdmanishshah","tweeter_id":"2390175907","geo":{"lt":null,"ln":null},"followers":640},"tweet_id":"899331367820959744"},{"url":"http:\/\/twitter.com\/JournalCancer\/statuses\/900061299580833792","license":"gnip","citation_ids":[24020726],"posted_on":"2017-08-22T18:25:10+00:00","author":{"name":"ACS Journal Cancer","url":"http:\/\/www.canceronlinejournal.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/708058565030907904\/JjiXwvyC_normal.jpg","description":"An interdisciplinary journal of the American Cancer Society.\n&emsp;&emsp;&emsp;&emsp;\nEditor-in-Chief: Fadlo R. Khuri, MD (@DrFadloKhuri)","id_on_source":"JournalCancer","tweeter_id":"19077568","geo":{"lt":33.749,"ln":-84.38798,"country":"US"},"followers":20036},"tweet_id":"900061299580833792"},{"url":"http:\/\/twitter.com\/Camicol1\/statuses\/900062166463721472","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-08-22T18:28:37+00:00","author":{"name":"camilla","image":"https:\/\/pbs.twimg.com\/profile_images\/868952044757032964\/XEY9-tRN_normal.jpg","description":"Quando sent\u00ec qualcosa che ti fa vibrare il cuore, non domandarti mai cosa sia, ma vivilo fino in fondo, perch\u00e9 quel brivido, quella sensazione si chiama Vita\ud83c\udf3b","id_on_source":"Camicol1","tweeter_id":"3043949210","geo":{"lt":null,"ln":null},"followers":84},"tweet_id":"900062166463721472"},{"url":"http:\/\/twitter.com\/leenakorpinen\/statuses\/900066162742091776","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-08-22T18:44:30+00:00","author":{"name":"L. Korpinen, MD, PhD","url":"http:\/\/www.leenakorpinen.fi","image":"https:\/\/pbs.twimg.com\/profile_images\/735029695914332160\/QEyiqxfB_normal.jpg","description":"Leena Korpinen tweets about: #Medicine, #Physiology, #Energy, #Health, #Nature, #Environment, #IoT, #Cloud #Mobile #DigitalHealth #Cybersecurity","id_on_source":"leenakorpinen","tweeter_id":"4705136182","geo":{"lt":61.49911,"ln":23.78712,"country":"FI"},"followers":2096},"tweet_id":"900066162742091776"},{"url":"http:\/\/twitter.com\/AV_icu\/statuses\/900085692482637825","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-08-22T20:02:06+00:00","author":{"name":"Anne Veinstein","image":"https:\/\/pbs.twimg.com\/profile_images\/754624497693691904\/bAWJhzpl_normal.jpg","id_on_source":"AV_icu","tweeter_id":"1349760805","geo":{"lt":null,"ln":null},"followers":24},"tweet_id":"900085692482637825"},{"url":"http:\/\/twitter.com\/talbotrlibrary\/statuses\/900091777952165893","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-08-22T20:26:17+00:00","author":{"name":"Talbot Library","url":"http:\/\/talbotresearchlibrary.wordpress.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/3055135669\/a57f377e0df6404c7272ecab3b6c3ab0_normal.png","description":"Talbot Library is the information hub for Fox Chase Cancer Center. We can help w\/EndNote, lit searches, systematic reviews, etc. We also have a sense of humor.","id_on_source":"talbotrlibrary","tweeter_id":"28645539","geo":{"lt":39.95234,"ln":-75.16379,"country":"US"},"followers":147},"tweet_id":"900091777952165893"},{"url":"http:\/\/twitter.com\/jdarsee\/statuses\/900136050097606656","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-08-22T23:22:12+00:00","author":{"name":"JR Hughes-Darsee MD","url":"http:\/\/www.mymedicalschool.com","image":"https:\/\/pbs.twimg.com\/profile_images\/272913406\/headshot_normal.jpg","description":"Medical writer","id_on_source":"jdarsee","tweeter_id":"40560522","geo":{"lt":41.09648,"ln":-73.97292,"country":"US"},"followers":263},"tweet_id":"900136050097606656"},{"url":"http:\/\/twitter.com\/giconnectInfo\/statuses\/900452789326827520","license":"gnip","rt":["GIcancerDoc"],"citation_ids":[24020726],"posted_on":"2017-08-23T20:20:49+00:00","author":{"name":"GI CONNECT","url":"http:\/\/giconnect.info\/","image":"https:\/\/pbs.twimg.com\/profile_images\/855343562405416960\/D4HEwo_C_normal.jpg","description":"Independent and international experts in GastroIntestinal (GI) oncology.\nPart of #theconnects","id_on_source":"giconnectInfo","tweeter_id":"3359087302","geo":{"lt":null,"ln":null},"followers":68},"tweet_id":"900452789326827520"},{"url":"http:\/\/twitter.com\/jlepping2013\/statuses\/900680013242093568","license":"gnip","rt":["GIcancerDoc"],"citation_ids":[24020726],"posted_on":"2017-08-24T11:23:43+00:00","author":{"name":"Jack Lepping","image":"https:\/\/pbs.twimg.com\/profile_images\/609414044735254528\/GSeQwGtV_normal.jpg","id_on_source":"jlepping2013","tweeter_id":"1054010256","geo":{"lt":null,"ln":null},"followers":183},"tweet_id":"900680013242093568"},{"url":"http:\/\/twitter.com\/JournalCancer\/statuses\/902218082466353157","license":"gnip","citation_ids":[24020726],"posted_on":"2017-08-28T17:15:27+00:00","author":{"name":"ACS Journal Cancer","url":"http:\/\/www.canceronlinejournal.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/708058565030907904\/JjiXwvyC_normal.jpg","description":"An interdisciplinary journal of the American Cancer Society.\n&emsp;&emsp;&emsp;&emsp;\nEditor-in-Chief: Fadlo R. Khuri, MD (@DrFadloKhuri)","id_on_source":"JournalCancer","tweeter_id":"19077568","geo":{"lt":33.749,"ln":-84.38798,"country":"US"},"followers":20036},"tweet_id":"902218082466353157"},{"url":"http:\/\/twitter.com\/DrAmitDangi\/statuses\/902219585885134848","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-08-28T17:21:26+00:00","author":{"name":"Dr Amit Dangi","image":"https:\/\/pbs.twimg.com\/profile_images\/889553551499837440\/rgpd2RWQ_normal.jpg","description":"Resident, Surgical Gastroenterology.                  Core Interest : HPB and colorectal","id_on_source":"DrAmitDangi","tweeter_id":"889551299921850368","geo":{"lt":20,"ln":77,"country":"IN"},"followers":73},"tweet_id":"902219585885134848"},{"url":"http:\/\/twitter.com\/bmassutis\/statuses\/902221262352723970","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-08-28T17:28:06+00:00","author":{"name":"Bartomeu Massuti","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000815179180\/824afb92a29dfe3e0ea3bfc1ec72d3d2_normal.jpeg","description":"Born in Majorca. Medical oncologist. Clinical researcher. Focused in lung cancer. World citizen. Major concerns: human inequality and blue planet environment","id_on_source":"bmassutis","tweeter_id":"77781024","geo":{"lt":null,"ln":null},"followers":1319},"tweet_id":"902221262352723970"},{"url":"http:\/\/twitter.com\/AngelesYrbas\/statuses\/902224259778535426","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-08-28T17:40:00+00:00","author":{"name":"Angeles Yrbas","url":"http:\/\/www.linkedin.com\/pub\/angeles-yrbas\/21\/785\/92a","image":"https:\/\/pbs.twimg.com\/profile_images\/523932083345829888\/HPNuObOS_normal.jpeg","description":"Farmaceutica. Calidad asistencial, seguridad del paciente, evaluacion de riesgo y tecnologia sanitaria. (Hospital. Oncologia. Auditoria. Regulacion)","id_on_source":"AngelesYrbas","tweeter_id":"429414986","geo":{"lt":-34.61315,"ln":-58.37723,"country":"AR"},"followers":396},"tweet_id":"902224259778535426"},{"url":"http:\/\/twitter.com\/lopezgovlaw\/statuses\/902225948204036097","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-08-28T17:46:43+00:00","author":{"name":"Jorge Luis Lopez Esq","url":"http:\/\/www.LopezGovLaw.com","image":"https:\/\/pbs.twimg.com\/profile_images\/612000460342448128\/Xgz6KteQ_normal.jpg","description":"Gov't Affairs Attorney | TV & Radio Analyst | Board: @AmericanCancer + @ACSCAN + @SFLRedCross + @BGCMia | Sponsor: @MiamiGives + @SurveySunday + @DailyPsalms365","id_on_source":"lopezgovlaw","tweeter_id":"92677101","geo":{"lt":25.77427,"ln":-80.19366,"country":"US"},"followers":6805},"tweet_id":"902225948204036097"},{"url":"http:\/\/twitter.com\/JournalCancer\/statuses\/905129721020764160","license":"gnip","citation_ids":[24020726],"posted_on":"2017-09-05T18:05:16+00:00","author":{"name":"ACS Journal Cancer","url":"http:\/\/www.canceronlinejournal.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/708058565030907904\/JjiXwvyC_normal.jpg","description":"An interdisciplinary journal of the American Cancer Society.\n&emsp;&emsp;&emsp;&emsp;\nEditor-in-Chief: Fadlo R. Khuri, MD (@DrFadloKhuri)","id_on_source":"JournalCancer","tweeter_id":"19077568","geo":{"lt":33.749,"ln":-84.38798,"country":"US"},"followers":20036},"tweet_id":"905129721020764160"},{"url":"http:\/\/twitter.com\/MiamiGives\/statuses\/905134161513639938","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-09-05T18:22:55+00:00","author":{"name":"Miami Gives","url":"https:\/\/www.facebook.com\/MiamiGives","image":"https:\/\/pbs.twimg.com\/profile_images\/684467898329481220\/7wpkgfWQ_normal.png","description":"Inspiring #Philanthropy in #Miami -- #care | #give | #share | #volunteer --sponsored by Marile & Jorge Luis Lopez, Esq. (@lopezgovlaw).","id_on_source":"MiamiGives","tweeter_id":"4300280902","geo":{"lt":25.77427,"ln":-80.19366,"country":"US"},"followers":2430},"tweet_id":"905134161513639938"},{"url":"http:\/\/twitter.com\/lopezgovlaw\/statuses\/905137691100053506","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-09-05T18:36:56+00:00","author":{"name":"Jorge Luis Lopez Esq","url":"http:\/\/www.LopezGovLaw.com","image":"https:\/\/pbs.twimg.com\/profile_images\/612000460342448128\/Xgz6KteQ_normal.jpg","description":"Gov't Affairs Attorney | TV & Radio Analyst | Board: @AmericanCancer + @ACSCAN + @SFLRedCross + @BGCMia | Sponsor: @MiamiGives + @SurveySunday + @DailyPsalms365","id_on_source":"lopezgovlaw","tweeter_id":"92677101","geo":{"lt":25.77427,"ln":-80.19366,"country":"US"},"followers":6805},"tweet_id":"905137691100053506"},{"url":"http:\/\/twitter.com\/ccsainc\/statuses\/905211013112373248","license":"gnip","rt":["JournalCancer"],"citation_ids":[24020726],"posted_on":"2017-09-05T23:28:18+00:00","author":{"name":"CCS Associates, Inc.","url":"http:\/\/www.ccsainc.com","image":"https:\/\/pbs.twimg.com\/profile_images\/808797803291951104\/aOh1cR1c_normal.jpg","description":"Scientific services company tweeting on cancer research, cancer prevention, and general health.","id_on_source":"ccsainc","tweeter_id":"3315496393","geo":{"lt":37.33939,"ln":-121.89496,"country":"US"},"followers":706},"tweet_id":"905211013112373248"}],"facebook":[{"url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1424228444358104&id=554459631334994","license":"public","citation_ids":[24020726],"posted_on":"2017-08-22T20:26:17+00:00","summary":"Retweeted ACS Journal Cancer (@JournalCancer):\n\nPatients w\/ #PancreaticCancer who received 2nd line fluoropyrimidine combo tx showed improved survival vs. FP alone https:\/\/t.co\/uM1Wa5k3Pv https:\/\/t.co\/lh9YSTCCja","author":{"name":"Talbot Research Library & Media Services","url":"https:\/\/www.facebook.com\/554459631334994","facebook_wall_name":"Talbot Research Library & Media Services","image":"https:\/\/graph.facebook.com\/554459631334994\/picture","id_on_source":"554459631334994"}}]}}